Vimarsana
Biggest News Aggregation in the World

Between Jun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Between Jun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Between Jun Today - Breaking & Trending Today

Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer - Vimarsana News

Positron emission tomography-guided treatment strategy may reduce need for chemotherapy for patients with HER2+ breast cancer

1. 3-year invasive disease-free survival among the PET-based treatment group was 94.8%. 2. There were fewer treatment-related and serious adverse events among patients in the PET-based group compared to the non-PET-based group. Evidence Rating Level: 1 (Excellent) Study Rundown: Human epidermal growth factor receptor 2-positive (HER2-positive) breast cancers are associated with a high risk of

Novel transcatheter heart valve may be effective for management of high-risk aortic regurgitation - Vimarsana News

Novel transcatheter heart valve may be effective for management of high-risk aortic regurgitation

1. The 30-day composite primary safety endpoint of > 40.5% was achieved for Trilogy TAVI. 2. 8% of patients who underwent Trilogy TAVI had passed at the 1-year follow-up. Evidence Rating Level: 1 (Excellent) Study Rundown: Surgery remains the primary intervention for native aortic regurgitation, but high-risk patients lack optimal alternatives. Traditional transcatheter heart valves

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer - Vimarsana News

Pembrolizumab enhances progression-free survival in patients with locally advanced cervical cancer

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential

High dose aflibercept reduced treatment burden in patients with diabetic macular edema - Vimarsana News

High dose aflibercept reduced treatment burden in patients with diabetic macular edema

1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events were comparable across all intervention groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Diabetic macular oedema (DMO) leads to vision loss in 5% of patients with diabetes. Anti-vascular endothelial growth factor (anti-VEGF) medications, such as

Novel prophylactic anticoagulation scoring tool helps stratify patients following lower limb trauma - Vimarsana News

Novel prophylactic anticoagulation scoring tool helps stratify patients following lower limb trauma

1. The 3-month symptomatic venous thromboembolism rate was 0.7% in patients with TRiP(cast) score < 7 and not receiving anticoagulation. 2. There was no significant difference between the control and intervention phases regarding secondary outcomes. Evidence Rating Level: 1 (Excellent) Study Rundown: Venous thromboembolism (VTE) is a well-recognized potential complication resulting from orthopedic trauma and